MTA (LY231514) is an antifolate that targets multiple folate-dependent enzymes. In this report, MTA transport was characterized in wild-type L1210 cells and variants with impaired membrane transport or polyglutamation. MTA influx via the reduced folate carrier was somewhat faster (approximately 30%) than that for methotrexate (MTX). Unlike MTX, MTA was rapidly polyglutamated in L1210 cells; hen...

INTRODUCTION The aim of the present investigation was to compare the efficacy of mineral trioxide aggregate (MTA) and 0.2% chlorhexidine (CHX) mixture to pure MTA, as a pulp capping material. METHODS AND MATERIALS The pulp of 24 lateral incisors and canines from four dogs were exposed and capped either with MTA or MTA+0.2% CHX. After 2 months the animals were sacrificed and the teeth were pre...

MTA is used widely in endodontic treatment as a pulp capping material, root-end filling material, and perforation repair. Although MTA has many favorable properties, long setting time is a clinical disadvantage. To overcome this problem many studies were performed. Hydration accelerators, such as citric acid, lactic acid, calcium chloride, and calcium lactate gluconate, were added during the mi...

OBJECTIVE The purpose of this study was to investigate and compare the crystalline structures of recently released MTA Plus (MTA-P), MTA Angelus (MTA-A), DiaRoot BioAggregate (BA) by X-ray diffraction (XRD) analysis. MATERIALS AND METHODS Phase analysis was carried out on powder and set forms of tested materials. The powder specimens placed into sample holders that were packed with a glass sl...

OBJECTIVES The effects of bone morphogenetic protein-2 (BMP-2) and enamel matrix derivative (EMD) respectively with mineral trioxide aggregate (MTA) on hard tissue regeneration have been investigated in previous studies. This study aimed to compare the osteogenic effects of MTA/BMP-2 and MTA/EMD treatment in MC3T3-E1 cells. MATERIALS AND METHODS MC3T3-E1 cells were treated with MTA (ProRoot, ...